Literature DB >> 2217174

Productive human immunodeficiency virus infection levels correlate with AIDS-related manifestations in the patient.

D Mathez1, D Paul, C de Bélilovsky, Y Sultan, J Deleuze, I Gorin, W Saurin, R Decker, J Leibowitch.   

Abstract

Mononuclear cells were obtained from 71 human immunodeficiency virus type 1 (HIV-1) seropositive subjects presenting and first visit either as asymptomatic or with minor symptoms and with CD4 lymphocytes greater than 550 per mm3 (group A, 35 patients) or as patients with AIDS, AIDS-related illnesses, or CD4 lymphocytes less than 400 per mm3 (group B, 36 patients). After 1-5 years of follow-up, 13 patients of group A had essentially retained their initial status (asymptomatics); the 22 others had suffered clinical or immunological deterioration (progressors). Frozen cells were thawed and submitted to lethal gamma-irradiation in vitro (4500 rads; 1 rad = 0.01 Gy) before they were cultured with normal phytohemagglutinin-stimulated lymphocytes to determine radiation-resistant HIV expression ex vivo (R-HEV). HIV antigenemia correlated with R-HEV values in 142 samples (r = 0.92, P less than 0.001) but was a less sensitive predictor of disease than R-HEV. R-HEV was detected in all specimens from patients with major AIDS-related illnesses or HIV-associated CD4 lymphopenia. In 77% of the progressors from group A, R-HEV detection preceded the onset of AIDS-associated disease or CD4 lymphopenia by 1 year (average). Conversely, R-HEV was low or was not detected in 36 sequential specimens from the 13 patients who remained asymptomatic over the following 2-5 years. Thus, persistently low HIV expression in vivo predicted a nondiseased state, whereas higher HIV expression levels seemed necessary for disease to occur. These data indicate that R-HEV is related to productive HIV infection in vivo, the latter acting as a determinant of AIDS-related illnesses. In view of this, measurement of HIV expression levels in the patient should be useful in antiviral efficacy trials.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2217174      PMCID: PMC54762          DOI: 10.1073/pnas.87.19.7438

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

Authors:  J M Lange; D A Paul; H G Huisman; F de Wolf; H van den Berg; R A Coutinho; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

2.  Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

Authors:  D Zagury; J Bernard; R Leonard; R Cheynier; M Feldman; P S Sarin; R C Gallo
Journal:  Science       Date:  1986-02-21       Impact factor: 47.728

3.  LAV/HTLV-III seroconversion and disease in hemophiliacs treated in France.

Authors:  D Mathez; J Leibovitch; Y Sultan; P Maisonneuve
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

4.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency.

Authors:  T Folks; D M Powell; M M Lightfoote; S Benn; M A Martin; A S Fauci
Journal:  Science       Date:  1986-02-07       Impact factor: 47.728

5.  Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection.

Authors:  J Goudsmit; J M Lange; D A Paul; G J Dawson
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

6.  Plasma viremia in human immunodeficiency virus infection.

Authors:  R W Coombs; A C Collier; J P Allain; B Nikora; M Leuther; G F Gjerset; L Corey
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

7.  Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro.

Authors:  M S Hirsch; S M Phillips; C Solnik; P H Black; R S Schwartz; C B Carpenter
Journal:  Proc Natl Acad Sci U S A       Date:  1972-05       Impact factor: 11.205

8.  HIV antigenaemia and virus isolation from plasma during primary HIV infection.

Authors:  H Gaines; J Albert; M von Sydow; A Sönnerborg; F Chiodi; A Ehrnst; O Strannegård; B Asjö
Journal:  Lancet       Date:  1987-06-06       Impact factor: 79.321

9.  Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection.

Authors:  J Goudsmit; F de Wolf; D A Paul; L G Epstein; J M Lange; W J Krone; H Speelman; E C Wolters; J Van der Noordaa; J M Oleske
Journal:  Lancet       Date:  1986-07-26       Impact factor: 79.321

10.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

View more
  8 in total

Review 1.  Retrovirus and filovirus "immunosuppressive motif" and the evolution of virus pathogenicity in HIV-1, HIV-2, and Ebola viruses.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

Review 2.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 3.  Quantitative molecular methods in virology.

Authors:  M Clementi; S Menzo; A Manzin; P Bagnarelli
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Prognostic value of immunological data, in vitro antibody production, and virus culture in vertical infection with HIV-1.

Authors:  M C García Rodriguez; I Bates; I de José; F Hawkins; R Martinez-Zapico; A Ferreira; G Fontán
Journal:  Arch Dis Child       Date:  1995-06       Impact factor: 3.791

5.  Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort.

Authors:  N L Michael; T Mo; A Merzouki; M O'Shaughnessy; C Oster; D S Burke; R R Redfield; D L Birx; S A Cassol
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

6.  Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.

Authors:  D Mathez; R F Schinazi; D C Liotta; J Leibowitch
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

7.  Differential requirements for HIV-1 replication in naive and memory CD4 T cells from asymptomatic HIV-1 seropositive carriers and AIDS patients.

Authors:  A Cayota; F Vuillier; D Scott-Algara; V Feuillie; G Dighiero
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

8.  Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes.

Authors:  K Saksela; C Stevens; P Rubinstein; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.